Here, we report that a binding inhibitor of lamin A (LA) and progerin called progerinin, improves aging-associated alterations in both in vitro and in vivo HGPS models, and consequently suggest that progerinin can be an effective treatment strategy for patients with HGPS. The gene discussed is LMNA; the disease is Hutchinson-Gilford progeria syndrome.